Range Low Price High Price Comment
30 days $391.02 $421.45 Wednesday, 1st May 2024 VRTX stock ended at $402.14. This is 2.38% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 3.68% from a day low at $392.47 to a day high of $406.90.
90 days $391.02 $437.00
52 weeks $320.01 $448.40

Historical Vertex Pharmaceuticals Incorporated prices

Date Open High Low Close Volume
May 01, 2024 $392.81 $406.90 $392.47 $402.14 1 236 091
Apr 30, 2024 $396.20 $396.69 $391.70 $392.81 1 727 278
Apr 29, 2024 $397.48 $399.31 $394.35 $396.20 604 503
Apr 26, 2024 $393.52 $399.63 $393.49 $397.48 677 777
Apr 25, 2024 $402.44 $403.88 $393.00 $397.70 787 230
Apr 24, 2024 $404.50 $406.83 $399.29 $400.76 786 338
Apr 23, 2024 $404.00 $406.74 $403.47 $404.91 1 069 746
Apr 22, 2024 $397.30 $406.34 $396.00 $399.92 1 325 042
Apr 19, 2024 $394.72 $396.98 $391.25 $394.28 1 302 907
Apr 18, 2024 $394.19 $396.14 $391.02 $393.48 942 971
Apr 17, 2024 $394.94 $398.11 $392.03 $393.10 879 631
Apr 16, 2024 $396.88 $398.49 $392.81 $394.17 693 810
Apr 15, 2024 $400.00 $402.49 $396.69 $397.36 1 372 621
Apr 12, 2024 $396.57 $400.14 $393.76 $396.55 1 164 746
Apr 11, 2024 $404.30 $404.69 $398.85 $400.23 1 044 251
Apr 10, 2024 $399.89 $401.00 $394.84 $397.58 1 012 069
Apr 09, 2024 $406.00 $406.45 $399.30 $404.48 721 018
Apr 08, 2024 $403.45 $404.60 $399.00 $404.22 745 908
Apr 05, 2024 $404.29 $409.93 $400.83 $406.67 691 470
Apr 04, 2024 $412.64 $412.64 $403.15 $404.01 937 224
Apr 03, 2024 $409.45 $414.96 $408.25 $408.81 703 747
Apr 02, 2024 $419.00 $420.87 $406.73 $409.42 974 479
Apr 01, 2024 $420.43 $421.45 $414.74 $420.48 767 528
Mar 28, 2024 $419.48 $420.67 $415.06 $418.01 1 053 576
Mar 27, 2024 $420.30 $420.42 $412.65 $417.32 905 394
Click to get the best stock tips daily for free!

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticalsorporated Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation... VRTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT